Telix Financial Statements From 2010 to 2026

TLX Stock   7.25  0.27  3.59%   
Telix Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Telix Pharmaceuticals' valuation are provided below:
Gross Profit
358.3 M
Profit Margin
0.0163
Market Capitalization
3.3 B
Enterprise Value Revenue
4.0677
Revenue
664.2 M
We have found one hundred twenty available fundamental trend indicators for Telix Pharmaceuticals Limited, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Telix Pharmaceuticals Limited current market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 3.6 B in 2026. Enterprise Value is likely to rise to about 101.4 M in 2026

Telix Pharmaceuticals Total Revenue

1.27 Billion

Check Telix Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Telix Pharmaceuticals' main balance sheet or income statement drivers, such as Other Operating Expenses of 1.2 B, Operating Income of 28 M or EBITDA of 83.8 M, as well as many indicators such as Price To Sales Ratio of 2.88, Dividend Yield of 0.53 or PTB Ratio of 5.77. Telix financial statements analysis is a perfect complement when working with Telix Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Telix Stock
Check out the analysis of Telix Pharmaceuticals Correlation against competitors.

Telix Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding187.5 M337.9 M169.3 M
Slightly volatile
Total Assets1.9 B1.8 B377.4 M
Slightly volatile
Total Current Liabilities364.3 M347 M84.7 M
Slightly volatile
Property Plant And Equipment Net181.9 M173.2 M28.9 M
Slightly volatile
Accounts Payable112.7 M107.4 M22.2 M
Slightly volatile
Cash223.2 M212.5 M94.8 M
Slightly volatile
Non Current Assets Total1.3 B1.3 B221.2 M
Slightly volatile
Cash And Short Term Investments223.2 M212.5 M92.6 M
Slightly volatile
Net Receivables217.7 M207.3 M45.3 M
Slightly volatile
Liabilities And Stockholders Equity1.9 B1.8 B377.1 M
Slightly volatile
Non Current Liabilities Total841.7 M801.6 M155.8 M
Slightly volatile
Total Liabilities1.2 B1.1 B240.4 M
Slightly volatile
Total Current Assets519.5 M494.8 M156.6 M
Slightly volatile
Short and Long Term Debt Total823.7 M784.5 M132.5 M
Slightly volatile
Good Will313 M298.1 M44.1 M
Slightly volatile
Inventory58.3 M55.5 M11.7 M
Slightly volatile
Other Current Assets20.4 M19.4 M7.5 M
Slightly volatile
Other Stockholder Equity720.6 M686.3 M273.3 M
Slightly volatile
Short Term Debt29.3 M28 M5.8 M
Slightly volatile
Current Deferred Revenue18 M17.2 M5.6 M
Slightly volatile
Intangible Assets619.5 M590 M110.9 M
Slightly volatile
Long Term Debt666.3 M634.6 M109.9 M
Slightly volatile
Capital Lease Obligations6.7 M12.2 MM
Slightly volatile
Net Invested Capital1.4 B1.3 B290.6 M
Slightly volatile
Property Plant And Equipment Gross76.8 M73.2 M20.3 M
Slightly volatile
Short and Long Term Debt22.9 M21.8 MM
Slightly volatile
Non Current Liabilities Other23.3 M27.4 M45.3 M
Slightly volatile
Net Working Capital709.6 M675.8 M173.4 M
Slightly volatile
Long Term Investments7.3 M5.5 M11.2 M
Slightly volatile

Telix Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses1.2 B1.2 B244.6 M
Slightly volatile
Depreciation And Amortization34.3 M32.7 MM
Slightly volatile
Interest Expense57.8 M55.1 M9.2 M
Slightly volatile
Selling General Administrative146.9 M139.9 M38.5 M
Slightly volatile
Total Revenue1.3 B1.2 B243.8 M
Slightly volatile
Cost Of Revenue593.5 M565.2 M119.1 M
Slightly volatile
Research Development269.7 M256.8 M55 M
Slightly volatile
Selling And Marketing Expenses103.2 M98.3 M22.9 M
Slightly volatile
Interest Income13.1 M12.5 M2.2 M
Slightly volatile
Reconciled Depreciation6.1 M7.8 M5.4 M
Slightly volatile

Telix Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation34.3 M32.7 M7.5 M
Slightly volatile
Capital Expenditures59.7 M56.9 MM
Slightly volatile
End Period Cash Flow108.8 M212.5 M87.9 M
Slightly volatile
Stock Based Compensation23.7 M22.6 M5.3 M
Slightly volatile
Dividends Paid43.8 M49.3 M53.8 M
Slightly volatile
Issuance Of Capital Stock854.1 K899.1 K34.2 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.883.0358393
Slightly volatile
Dividend Yield0.530.590.647
Slightly volatile
PTB Ratio5.776.075366.1511
Pretty Stable
Days Sales Outstanding57.7260.75749.1 K
Slightly volatile
Book Value Per Share1.941.84350.5899
Slightly volatile
Average Payables70.5 M79.3 M86.5 M
Slightly volatile
Stock Based Compensation To Revenue0.01910.02011.9971
Slightly volatile
Capex To Depreciation0.891.571.2225
Pretty Stable
PB Ratio5.776.075366.1511
Pretty Stable
EV To Sales3.323.495326
Slightly volatile
Inventory Turnover16.2410.51139.5713
Slightly volatile
Days Of Inventory On Hand32.9934.724513.5 K
Slightly volatile
Payables Turnover3.215.43892.2123
Slightly volatile
Sales General And Administrative To Revenue0.160.1723.7791
Slightly volatile
Average Inventory424.9 K533 K514.1 K
Slightly volatile
Research And Ddevelopement To Revenue0.20.213151.668
Slightly volatile
Capex To Revenue0.08980.04720.11
Slightly volatile
Cash Per Share0.380.62960.4329
Slightly volatile
Days Payables Outstanding63.7567.108712.5 K
Slightly volatile
Intangibles To Total Assets0.290.50150.22
Slightly volatile
Current Ratio1.351.425915.8654
Slightly volatile
Receivables Turnover6.316.00751.6614
Slightly volatile
Shareholders Equity Per Share1.941.84350.59
Slightly volatile
Debt To Equity1.321.26060.3044
Slightly volatile
Capex Per Share0.180.1740.0321
Slightly volatile
Average Receivables173.2 M164.9 M80.2 M
Slightly volatile
Revenue Per Share3.873.68930.7109
Slightly volatile
Interest Debt Per Share2.622.49260.4176
Slightly volatile
Debt To Assets0.470.4430.0892
Slightly volatile
Graham Number1.132.170.6769
Slightly volatile
Operating Cycle90.7195.481914.7 K
Slightly volatile
Price Book Value Ratio5.776.075366.1511
Pretty Stable
Days Of Payables Outstanding63.7567.108712.5 K
Slightly volatile
Company Equity Multiplier5.542.84594.7655
Pretty Stable
Long Term Debt To Capitalization0.550.51910.1058
Slightly volatile
Total Debt To Capitalization0.590.55760.1505
Slightly volatile
Debt Equity Ratio1.321.26060.3044
Slightly volatile
Quick Ratio1.21.265815.7299
Slightly volatile
Net Income Per E B T0.811.3530.9369
Slightly volatile
Cash Ratio0.580.612515.19
Slightly volatile
Cash Conversion Cycle26.9528.37322.1 K
Pretty Stable
Days Of Inventory Outstanding32.9934.724513.5 K
Slightly volatile
Days Of Sales Outstanding57.7260.75749.1 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio3.353.19261.2013
Slightly volatile
Price To Book Ratio5.776.075366.1511
Pretty Stable
Fixed Asset Turnover5.167.19023.7429
Slightly volatile
Debt Ratio0.470.4430.0892
Slightly volatile
Price Sales Ratio2.883.0358393
Slightly volatile
Asset Turnover0.740.70320.2357
Slightly volatile
Price Fair Value5.776.075366.1511
Pretty Stable

Telix Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.6 B3.4 B1.8 B
Slightly volatile
Enterprise Value101.4 M96.6 M71.7 M
Slightly volatile

Telix Fundamental Market Drivers

Forward Price Earnings1000
Cash And Short Term Investments212.5 M

About Telix Pharmaceuticals Financial Statements

Telix Pharmaceuticals investors use historical fundamental indicators, such as Telix Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Telix Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue17.2 M18 M
Total Revenue1.2 B1.3 B
Cost Of Revenue565.2 M593.5 M
Stock Based Compensation To Revenue 0.02  0.02 
Sales General And Administrative To Revenue 0.17  0.16 
Research And Ddevelopement To Revenue 0.21  0.20 
Capex To Revenue 0.05  0.09 
Revenue Per Share 3.69  3.87 
Ebit Per Revenue 0.02  0.02 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.